Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Source: Senate LDA
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
National Defense Authorization Act for Fiscal Year 2016
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
National Defense Authorization Act for Fiscal Year 2016
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
National Defense Authorization Act for Fiscal Year 2016
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
Implementation of tax provisions of the ACA and tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · third_quarter · Q3
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Implementation of tax provisions of the ACA and tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · second_quarter · Q2
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Implementation of tax provisions of the ACA and tax reform policies.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · first_quarter · Q1
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · third_quarter · Q3
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · first_quarter · Q1
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · third_quarter · Q3
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · second_quarter · Q2
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · first_quarter · Q1
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2015 · fourth_quarter · Q4
Regulatory implementation of various tax provisions in the health reform law.
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2015 · third_quarter · Q3
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory implementation of various tax provisions in the health reform law.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2015 · second_quarter · Q2
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Postal reform proposals and their impact on 6 day mail delivery.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2015 · first_quarter · Q1
Pharmacy issues related to the 2015 annual defense reauthorization (113th Congress - HR 4438)
Postal reform proposals and their impact on 6 day mail delivery.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General legislative and regulatory issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales price. Medicare audit and preferred network restrictions. S. 867, HR 4437, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock in, etc.).
Policies related to FEHBP's pharmacy benefit (HR 1367). Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR. Specialty pharmacy tiering restrictions (HR 460). Regulatory implementation of a pathway for the approal of biosimilars. REMs. 340b program reform. Policies placing restrictions on pharmcy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act). S. 867, HR 4437, HR 4577.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · first_quarter · Q1
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · 4A
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · Q4
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · third_quarter · Q3
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · first_quarter · Q1
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 1409, Legislation to exempt health care providers (including pharmacies) from the antitrust laws for purposes of negotiating with payers.
Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act for 2012
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · fourth_quarter · Q4
Exclusion of specialty distributors' prompt pay discounts from the definition of averages sales price Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap, drug copay waivers. Reform proposals that impact Medicaid such as statutory changes to average manufacture price. General regulatory changes to the Medicare Part D program.
HR. 1204--Pharmacies Antitrust Carve-out Legislation
Regulatory policies related to health reform, structure, PBM and drug benefits--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH (ARRA, HR 1)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · third_quarter · Q3
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · second_quarter · Q2
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · first_quarter · Q1
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199
H.R. 1204--Pharmacies Antitrust carve out legislation
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3950 and HR 4872 (PPRACA)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · fourth_quarter · Q4
Establishment of a regulatory pathway for biogenerics/biosimilars--S. 1679, HR 1427, HR 1548, S. 726, HR 3962, HR 3950 Items related to the regulatory implementation of HITECH, HR 1 Items relating to health care reform bills, structure, pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act
Items related to reverse settlement payments between manufacturers--HR 1706, S. 369, HR 3590; HR 3962 Items related to oversight of the federal employees health benefits program and its pharmacy benefit Design and coverage of pharmacy benefits in new Health Exchanges/Gateways as well as pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act HR 4199, PHARMACY bill, items related to restricting PBMs ability to manage prescription drug benefits.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · third_quarter · Q3
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392, HR 3200 Various regulatory items related to Medicare Part B, Part D and workers' compensation Health reform proposals that would impact Part D such as formulary requirements, relaxation of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes--America's Healthy Future Act, S. 1679, HR 3200
H.R. 1204--Pharmacists Antitrust carve out legislation
Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3200, S. 1679, HR 1427, HR 1548, S. 726 Items related to the regulatory implementation of HITECH, HR 1 Items relating to health care reform bills, structure, pharmacy benefit managers transparency requirements--America's Healthy Future Act, HR 3200, S. 1679
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · second_quarter · Q2
Items related to reverse settlement payments between manufacturers, HR 1706 Changing the definition of first-to-file between manufacturers, S 1315 Items related to oversight of the federal employees health benefit program and its pharmacy benefit
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392 Various regulatory items related to Medicare Part B, Part D and workers compensation Expansion of Medicaid pricing rebates, S 330, Hr 904, S 547 Various health reform proposals that would impact Part D and Medicare Advantage
Establishment of a regulatory pathway for biogenerics, HR 1427, HR 1548, S 726 Physician Sunshine Act, S. 301 Health information technology & changes to the HIPAA privacy laws, H.R. 1 General items relating to health care reform bills, structure, public plan: Affordable Health Care Choices & TriCommittee bill
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · first_quarter · Q1
Items related to reverse settlement payments between manufacturers, H.R. 1706
H.R. 1204, Pharmacists' Antitrust carve out; H.R. 1409/S. 560, Employee Free Choice Act
Exclusion of specialty distributors' prompt payment discounts from the definition of average sales price, H.R. 1392 Various regulatory items related to the Medicare Part D benefits Expansion of Medicaid pricing, S. 330, HR. 904, S. 547
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · fourth_quarter · Q4
Genetic Information Nondiscrimination Act (HR 493/S 358) Issues relating to promoting health information technology/EMR/privacy (HR 3800/S 1693/HR 6898/HR 6357)
Issues relating to the DOL's propsoed disclosure of compensation for service fee providers under ERISA Providing an antitrust exemption for independent pharmacies HR 800 /S 1041 -- issues relating to amending the NLRA bargaining and organizing
HR 1038/HR 1956/HR5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--issues related to bringing generics to market in a timely fashion S. 596/S 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · third_quarter · Q3
Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA Providing an antitrust exemption for independent pharmacies (HR 971/S 885/S 2161)
HR 1038/HR 1956/S 1695/HR 5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
Medicare Part D: prompt pay/EFT for pharmacies (HR 1474/S 1827/S 1954/HR 6331), Changes to the part D benefit (HR 3162/S 2499/HR 6331), Electronic prescribing and eRx for controlled substances (HR 4296/S 2408/HR 6331), access to Medicare Data (HR 6388/S 1507/HR 6331), various regulatory issues related to Part D benefit. Medicare Part B: Changes to the competitive acquisition program for biologics (HR 3162) and prompt pay exclusion for distribution (HR 2770); AMP changes (HR 6331)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · second_quarter · Q2
Items relating to the implementation of PL 110-85, the FDA reauthorization Act of 2007 HR 1038/HR 1956/S. 1695/HR 5629--regulatory pathway for generic biologics S. 1088/S. 28/S. 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980--internet pharmacy regulations Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA
Medicare Part D: prompt pay/EFT for pharmacies (HR 1474/S 1827/ S 1954/HR 6331), changes to the Part D benefit (HR 3162/S 2499/HR 6331), electronic prescribing (H.R. 4296/S 2408/ HR 6331), Access to Medicare Data (H.R. 6388/S 1507), various regulatory issues related to implementing the Medicare Part D benefit. Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exculsion from Part B (HR 2770) Items related to the definition of Medicaid Average Manufacture Price (AMP) as espoused by the 2005 Deficit Reduction Act. (HR 3700/HR 6331)
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Pharmacy issues related to the annual defense reauthorization.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to the annual defense reauthorization (HR 1735,S 1376).
Postal reform proposals and their impact on 6 day mail delivery.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Regulatory implementation of various tax provisions in the health reform law.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees, pedigree, pathway for biosimilars, REMs). Restrictions on specialty tiering. HR 460.
Pharmacy issues related to the annual defense reauthorization (HR 4438)
Postal reform proposals and their impact on 6 day mail delivery.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduc.
Trans Pacific Partnership trade agreements impact on biosimilar drugs market exclusivity length.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for puposes of negotiating with payers (HR 1409, HR 1946, HR 1839)
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Implementation of Zadroga Health Care Act; Legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as EGWP waivers and MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of Average Manufacture Price in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs; regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Zadroga implement.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
Items related to reverse settlement payments between manufacturers--HR 1706, S 369; Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489; Regulatory design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements; Policies related to restricting PBMS' ability to manage prescription drug benefits-- HR 4199; PBM Audit Reform & Transparency Act--HR 5234.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
H.R. 1204--Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 1204--Pharmacies Antitrust carve out legislation
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392, HR 3200 Various regulatory items related to Medicare Part B, Part D and workers' compensation Health reform proposals that would impact Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing Medicare Part D's coverage gap-- HR 3962, Affordable Health Care for America Act HR 3950, Patient Protection and Affordable Care Act
H.R. 1204 -- Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Items related to reverse settlement payments between manufacturers--HR 1706, S. 369 Items related to oversight of the federal employees health benefits program and its pharmacy benefit Design and coverage of pharmacy benefits in new Health Exchanges/Gateways as well as pharmacy benefit managers transparency requirements--America's Healthy Future Act, S. 1679, HR 3200
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
H.R. 1204, Pharmacists Antitrust carve out
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Establishment of a regulatory pathway for biogenerics, H.R. 1427, H.R. 1548, S. 726 Physician Sunshine Act, S. 301 Health information technoglogy & changes to the HIPAA privacy law, H.R. 1
Filing targets: Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Medicare Part D: prompt pay/EFT for pharmacies (HR 6331/MIPAA), changes to Part D benefit (HR 3162/HR 6331), Electronic prescribing & eRx for controlled substances (HR 63331, agency), access to Medicare Data (HR 6331/MIPAA), various regulatory issues related to Part D benefit. Medicare Part B: changes to the competitive acquisition program for biologics (regulatory) and prompt pay exclusion for specialty distributors (HR 2770), AMP changes (HR 6331 & MIPAA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Legal Services Corporation, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Genetic Information Nondiscrimination Act (HR 493/S 358), Health Information technolgoy (HR 3800/S 1693/HR 6898/HR 6357)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Genetic Information Nondiscrimination Act (HR 493/S 358), Health information technology (HR 3800/S 1693)
providing an antitrust exemption for independent pharmacies (HR 971/S. 885/S 2161)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), SENATE, White House Office